Zum Inhalt springen
Home » Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome The post Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a…

Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome